The company has roaming agreements with 400+ cellular carriers worldwide, which are accessible from over 200 cruise ships. In those cases, travelers’ devices will automatically connect to the network ...
MOMA Therapeutics on Wednesday said it added the next-generation PARP1 inhibitor MOMA-989 to its pipeline of drug candidates and anticipates filing an investigational new drug application by year end ...